PPARγ pathway activation results in apoptosis and COX-2 inhibition in HepG2 cells

Ming-Yi Li, Hua Deng, Jia-Ming Zhao, Dong Dai, Xiao-Yu Tan

INTRODUCTION

Peroxisome proliferator-activated receptors (PPARs) are transcription factors belonging to the nuclear receptor gene family. PPARs bind to specific response elements as heterodimers with the retinoid X receptor and activate transcription in response to a variety of endogenous and exogenous ligands, including some polyunsaturated fatty acids, arachidonic acid metabolites, and some anti-diabetic drugs and non-steroidal anti-inflammatory drugs. Recently, PPAR subfamilies have been defined as PPARα, PPARβ, and PPARγ. Three PPAR isoforms differ in their tissue distribution and ligand specificity. PPARα is predominantly expressed in tissues exhibiting high catabolic rate of fatty acids, whereas PPARβ expression is ubiquitous, and its physiological role is not clear. PPARγ is expressed predominantly in adipose tissue, the adrenal gland, spleen, large colon and the immune system. Several lines of evidence indicate that PPARγ plays an important role in regulating adipocyte differentiation and glucose homeostasis. Both PPARα and PPARγ have been shown to be involved in anti-inflammatory reactions mediated by arachidonic acid metabolites. PPARα binds to, and is activated by leukotriene B4, and its level is regulated at the transcriptional level by anti-inflammatory glucocorticoids. PPARγ is activated by prostaglandin D3 metabolite 15-deoxy-Δ12,14-prostaglandin J2 (15 d-PGJ2) and synthetic anti-diabetic thiazolidinedione drugs, resulting in down-regulation of the expression of pro-inflammatory genes and inhibition of tumor cell growth.

Cyclooxygenase (COX) is a rate-limiting enzyme, catalyzing the initial step in biosynthesis of prostaglandins (PGs) from arachidonic acid. COX is encoded by two separate genes, COX-1 and COX-2, both of which participate in formation of a variety of eicosanoids including PGD, PGE, PGF, and thromboxane A. COX-1 is expressed constitutively in most tissues and has been proposed to be a house-keeping gene, which is involved in cytoprotection of gastric mucosa, vasodilation in kidney, and control of platelet aggregation. In contrast, COX-2 is an inducible immediate-early gene that is upregulated by various stimuli including mitogens, cytokines, growth factors, and tumor promoters. Previous studies have demonstrated that COX-2 expression is aberrantly increased in (various) human epithelial cancers in colorectum, esophagus, stomach, lung, and bladder. These findings suggest that up-regulation of COX-2 may be a common mechanism in epithelial carcinogenesis. Recently, PPARγ ligands was found to suppress COX-2 expression in fetal hepatocytes and in macrophase-like differentiated U937 cells. However, other authors reported that 15d-PGJ2 induced the expression of COX-2 in immortalized epithelial and colorectal cancer cells. The mechanisms for the different regulation of COX-2 expression by PPARγ ligands remain to be elucidated. In the present study, we wanted to investigate the effect of PPARγ activation on cell growth and apoptosis, and to investigate underlying mechanism in regard to the expression of COX-2 and Bcl-2 members in HepG2 cells.

MATERIALS AND METHODS

Cell culture

Human liver cancer cell line HepG2 was provided by the American Type Culture Collection. Cells were grown in RPMI-1640 medium supplemented with 15 % newborn bovine serum, penicillin G (100 kU·L⁻¹) and kanamycin (0.1g/L) at 37 °C in
the 5% CO₂ incubator. Cells were grown on 96-well plates for MTT assay. [³H] thymidine incorporation and DNA fragmentation enzyme-linked immunosorbent assay (ELISA). For the experiment, cells were grown in fresh serum-free medium, incubated for 6 hours, and treated with experimental reagents.

**MTT cell viability assay**

Cell growth was assessed by a modified MTT assay. About 2x10⁵ cells/well were plated in 96-well microtiter plates and incubated overnight. Cells were then treated with troglitazone for 48 h in various concentrations. Then 10 µl stock MTT (0.5 g/L) was added to each well, and the cells were further incubated at 37°C for 4 h. After supernatant was removed, 100 µl of 0.04 M HCl in isopropanol was added to each well to solubilize the formazan products. The absorbance at the wavelength of 570 nm was measured by a micro-ELISA reader. The negative control well contained medium only. The ratios of the absorbance of treated cells relative to those of the control wells were calculated and expressed as percentage of growth inhibition.

**[³H] thymidine incorporation**

Cells were planted in 96-well plates and grown for 24 h after being starved by growing in the serum-free medium for 48 h. Then, they were treated with troglitazone for 48 h and labeled with 5 µCi of [³H] thymidine for 4 h. Radioactivity was detected using a Beckman L5 counter, after the reaction was washed three times.

**Hoechst 33258 staining**

Cells were fixed with 4% formaldehyde in phosphate-buffered saline (PBS) for 10 min, stained by Hoechst 33258 (10 µg/mL) for 1 h, and subjected to fluorescence microscopy. After treatment with troglitazone, morphologic changes, including reduction in cell size and nuclear chromatin condensation, were observed.

**DNA ladder demonstration**

After induction of apoptosis, cells (7x10⁵/sample, both attached and detached cells) were lysed with 150 µl hypotonic lysis buffer (edetic acid 10 mM, 0.5% Triton X-100, Tris-HCl, pH 7.4) for 15 min on ice and were precipitated with 2.5% buffer (edetic acid 10 mM, 0.5% Triton X-100, Tris-HCl, pH 7). polyethylene glycol and 1 M NaCl for 15 min at 4°C. After centrifugation, 20 µl of 0.25 N sodium hydroxide was added to each well to solubilize the DNA ladder demonstration. The absorbance at the wavelength of 570 nm was measured by a micro-ELISA reader. The negative control well contained medium only. The ratios of the absorbance of treated cells relative to those of the control wells were calculated and expressed as percentage of growth inhibition.

**Detection of DNA fragmentation**

HepG2 cells were grown in 96-well plates. The cells were incubated with various doses of troglitazone for 48 h. DNA fragmentation was detected using an enzyme-linked immunosorbent assay (ELISA) kit (Roche). This assay was based on a quantitative sandwich enzyme-immunoassay directed against cytoplasmic histone-associated DNA fragments. Briefly, the cells were incubated in 200 µl of lysis buffer. After centrifugation, 20 µl of the supernatant was reacted overnight at 4°C in streptavidin-coated wells with 80 µl of biotinylated anti-histone antibody and peroxidase-conjugated anti-DNA antibody. After washing, the immunocomplex-bound peroxidase was probed with 2,2’-azino-di-[3-ethylbenzthiazoline sulfonate] for spectrophotometric detection at 405 nm.

**TUNEL reaction**

TUNEL reaction was done using apoptosis detection system (Cayman). Cells were fixed overnight at 4°C with 4% paraformaldehyde in PBS. The samples were washed three times with PBS and permeabilized by 0.2% Triton X-100 in PBS for 15 min on ice. After washed twice, cells were equilibrated at room temperature for 15 to 30 min in equilibration buffer (potassium cacodylate 200 mM, dithiothreitol 0.2 mM, bovine serum albumin 0.25 g/L, and cobalt chloride 2.5 mM in 25 mM Tris-HCl, pH 6.6), and then incubated in a solution containing 5 µM fluorescein-12-dUTP, 10 µM dATP, 100 µM edetic acid, and terminal deoxynucleotidyl transferase at 37°C for 1.5 h in a dark chamber. The tailing reaction was terminated by 2×standard saline citrate (SSC). The samples were washed three times with PBS and analyzed by fluorescence microscopy. At least 1000 cells were counted, and the percentage of TUNEL-positive cells was determined.

**RNA isolation and northern blotting**

After incubation with different doses of troglitazone for 6 h, cells were washed with RPMI. Total RNA was extracted from adherent cells using RNeasy Mini kits (Sigma) as described previously[37]. 30 mg of total RNA from each sample was separated on agarose/formaldehyde gels and transferred to nylon membranes. The membrane was hybridized with probes for COX-2 and for GAPDH as a reference.

**RT-PCR for COX-2**

Total RNA was extracted from cells using TRIzol® (Life). COX-2 and beta-actin mRNA were detected by polymerase-chain-reaction following reverse transcription-(RT-PCR) as described[30]. Primers for beta-actin were: sense 5’-ATCT-GGCACGACACCTCTAACAAGTGAGCTGGC-3’ and antisense 5’-CGTCTACCTCTCCTGTGTCATGAC-3’.

**Western blotting analysis**

The cells were lysed in a lysis buffer (hepes 25 mM, Triton X-100 1.5%, sodium deoxycholate 1%, SDS 0.1%, NaCl 0.5 M, edetic acid 5 mM, NaF 50 mM, sodium vanadate 0.1 mM, phenylmethylsulfonyl fluoride (PMSF) 1 mM and leupeptin 0.1 g/L, pH 7.8) at 4°C with sonication. The lysates were centrifuged at 15 000 g for 15 min and the concentration of the protein in each lysate was determined with Coomassie brilliant blue G-250. Loading buffer (42 mM Tris-HCl, containing 10% glycerol, 2.3% SDS, 5% 2-mercaptoethanol and 0.002% bromophenol blue) was then added to each lysate, which was subsequently boiled for 3 min and then electrophoresed on a SDS-polyacrylamide gel. Proteins were transferred onto a nitrocellulose filter and incubated separately with the antibodies against Bcl-2, Bak, Bcl-xL, and COX-2, and then labeled with peroxidase-conjugated secondary antibodies. The reactions were visualized using the enhanced chemiluminescence reagent (Sigma). The results were approved by repeating the reactions 2 times.

**Evaluation of PGE2 production**

To determine the levels of PGE2, HepG2 cells were treated with different concentrations of troglitazone for 24 h. The quantity of PGE2 in supernatants was immediately determined with the PGE2 Enzyme Immunoassay kit (Caymen Chemical) according to the manufacturer’s instructions. Data were recorded using a Dynatech MR50000 microplate reader and normalized to micrograms of protein.
Assessment of caspase-3 activity
Caspase-3 activity was evaluated using a caspase assay kit following instructions of the manufacturer. In brief, caspase-3 fluorogenic substrate (Ac-DEVD-AMC or Ac-IETD-AMC) was incubated with JTE522-treated cell for 1 h at 37 °C, then AMC released from Ac-DEVD-AMC or Ac-IETD-AMC was detected using a fluorometric plate reader with an excitation wavelength of 380nm and an emission wavelength of 420-460nm.

Statistical analysis
Data were presented as the mean ± standard error, unless otherwise indicated. Multiple comparisons were examined for significant differences using analysis of variance, followed by individual comparisons with the Bonferroni post-test. Comparisons between two groups were made with the Student t test. P<0.05 was considered significant.

RESULTS
Effects of PPARγ activation on cell proliferation and cell viability
HepG2 cells were incubated with various does of troglitazone for 48 h. MTT assay showed that troglitazone significantly inhibited cell viability. The inhibition was dependent on dose of troglitazone administered (Figure 1A). Application of troglitazone also resulted in a reduction of [³H] thymidine uptake in a dose-dependent manner (Figure 1B).

Influence of PPARγ activation on apoptosis
Effect of PPARγ activation on apoptosis was assessed by staining with Hoechst 33258, TUNEL reaction, DNA fragmentation demonstration on an agarose gel and by ELISA. The initiating effect of PPARγ activation on apoptosis was confirmed in HepG2 cell, the morphologic changes included reduction in cell size and nuclear chromatin condensation visualized by Hoechst 33258 staining. The apoptotic index was also increased by treatment with different concentration of troglitazone from 3.2±1.2 % to 53±2.6 %. Agarose gel electrophoresis showed DNA ladder pattern in the exposed HepG2 cells (Figure 2). The PPARγ pathway-induced apoptosis was further demonstrated in quantitative measurement of cytoplasmic histone-associated DNA fragment by ELISA. As shown in Figure 3, troglitazone induced significant increase in DNA fragmentation in a dose-dependent manner.

Figure 2 DNA ladder pattern formation in HepG2 cells after treatment with TGZ. Cells were treated with TGZ for 48 h and the formation of oligonucleosomal fragments was determined by 1.5 % agarose gel electrophoresis: M) DNA markers; 1) control; 2) 10µM TGZ; 3) 30µM TGZ.

Down-regulation of COX-2 associated with the PPARγ activation
The fact that the COX-2 promoter contains a PPRE indicates that COX-2 might be one of the downstream targets of the PPARγ pathway. In the present study, COX-2 expression was observed in HepG2 cells treated with vehicle or 30 µM troglitazone. After 6, 12, 24 and 48 h of the treatment, cells were harvested. COX-2 mRNA was analysed by RT-PCR (4A) and Northern blotting (4B), and its translation product was demonstrated by Western blotting (4C). As shown in Figure 4, no significant change was detected during the first 6 h of treatment when compared with the control. After treatment with 30 µM troglitazone for 12 h, the expression of COX-2 was inhibited.

Effects of PPARγ activation on expression levels of Bcl-2, Bcl-xL, Bak and Bak
To further elucidate the mechanisms of troglitazone-induced apoptosis in HepG2 cells, we assessed the involvement of bcl-2 family proteins in the process by Western blotting. Expression of Bak protein was up-regulated 6 h after 20 µM troglitazone treatment and remained elevated to 24 h. Expression level of Bak protein was also elevated 12 h after the treatment with 30 µM troglitazone and declined at 48 h. On the contrary, Bcl-2

Figure 3 DNA fragmentation by ELISA assay, as measured by absorbance (OD 450 values). HepG2 cells cultured for 48 h in the presence of TGZ resulted in dose dependent DNA fragmentation. P<0.05, P<0.01 compared to respective control.

Absorbance (OD450nm)

Concentration (µM)

0

0.1

0.2

0.3

0.4

0.5

0.6

0.7

0.8

0.9

Figure 1 Effect of TGZ on growth of HepG2 cells. HepG2 cells were incubated with various concentrations of TGZ for 48 h: (A) MTT assay; (B) [³H] thymidine uptake assay. The value was represented as mean ±SEM (n=3). P<0.01 versus corresponding control group.

Inhibition rate (%)

Concentration (µM)

0

10

20

30

40

50

90

80

70

60

50

40

30

20

10

0

Thymidine incorporation (% control)

Concentration (µM)

0

10

20

30

80

70

60

50

40

30

20

10

0
protein expression was down-regulated at 6 h and undetectable at 24 h. No significant change was observed in the expression of bcl-xL protein (Figure 5).

**Change in caspase-3 activity associated with PPARγ activation**

In consideration of frequent involvement of caspases activation in apoptosis, caspase-3 activity was assessed in HepG2 cell, treated with 20 µM troglitazone. As shown in Figure 7, the caspase-3 activity increased with the treatment, the reaction was time-dependent.

**DISCUSSION**

Potent effects of PPARγ on cell proliferation and cell cycling have been described. PPARγ ligands can trigger cell cycle arrest in NIH3T3 cells and HIB-1B cells. PPARγ ligands can also induce terminal differentiation and withdrawal of human liposarcoma cells from the cell cycle. Importantly, PPARγ ligands have been found to slow down the progression of advanced liposarcoma in humans. Given the expression of PPARγ in nonadipose tissues, the effect of PPARγ on human breast cancer, gastric cancer, prostate cancer, colon cancer and transitional cell, bladder cancer have been explored. Treatment of cultured breast cancer cells with troglitazone results in cell growth arrest and promotes differentiation. Troglitazone has also been shown to inhibit tumor growth and induce apoptosis in human breast cancer cells in vitro and in BNX mice. Moreover, another PPARγ ligand, GW7845, has been shown to decrease tumor incidence, tumor growth and tumor burden in the NMU induced mammary carcinoma. These data suggest that PPARγ ligands may be used as novel, nontoxic and selective chemotherapeutic agents for human breast cancers. In the present study, our results have shown that activation of PPARγ by troglitazone inhibits cell growth and induces apoptosis in human liver cancer HepG2 cells. We confirmed that the induction of apoptosis was mediated through down-regulation of COX-2 and Bcl-2 expression, and up-regulation of Bax and Bak expression. The down-regulation of COX-2 was coincident with down-regulation of the production of PGE2. The activity of Caspase-3 was increased after treatment with 30 µM PPARγ ligand troglitazone in a time-dependent manner.

Meade et al. have demonstrated that COX-2 expression is enhanced by peroxisome proliferators, including some fatty acids, PGs and NSAIDs, as well as the prototypical peroxisome proliferator WY-14,643, in mammary and colon epithelial cells, presumably through PPARα. Yang et al. showed that activation of PPAR pathway by ciglitazone induced apoptosis and inhibition of COX-2 expression in human colon cancer cells HT-29, but the result was not approved in an observation by Lefebvre et al. Our data showed that PPARγ activation inhibited the expression of COX-2. The discrepancy may be caused by different cell types used in these groups.

Overexpression of COX-2 plays important roles in cell adhesion, apoptosis and angiogenesis. Numerous epidemiological studies suggest that use of nonsteroidal anti-inflammatory drugs
(NSAIDs) decreases the incidence of gastrointestinal cancers and COX-2 is recognized as a major target of NSAIDs[65-70]. Inhibition of COX-2 by NSAIDs or COX-2-specific inhibitors causes cell death in cancer cells, indicating that COX-2 may be used as an important molecular target for prevention and therapy in gastrointestinal cancers[65-70]. The mechanism of COX-2 expression remains unclear. Subbaramaiyah and colleagues have shown that PPARγ can inhibit COX-2 expression.

In the present study, the levels of PGE$_2$ were decreased in a time-dependent manner after the treatment with 30 μM troglitazone, and were correlated with the change in COX-2 expression. This is in agreement with previous observations in other cell lines[71-73]. Thus, excessively synthesized PGE$_2$ mediated by overexpression of COX-2 is believed to play an important role in neoplasma formation. Inhibition of COX-2 activity may at least partly explain the chemopreventative effect of activated PPAR pathway in human liver cancer.

Apoptosis is characterized by a series of distinct morphological and biochemical changes. Several apoptosis-related genes have been found. One group of apoptosis regulatory genes is the Bcl-2 family[74-79]. Of these genes, Bcl-2, Bcl-x$_L$, Bcl-2, Bax, Bcl-x$_L$, Bak, Bad and Bik are proapoptotic. In this study, overexpression of Bax and Bak, and suppression of the expression of Bcl-2 were found during the apoptosis induced by PPARγ activation. These data confirm the role of these proteins in troglitazone-induced apoptosis in HepG2 cells. In addition, the activity of caspase-3 was also found to be elevated during the apoptotic process induced by PPARγ activation.

In summary, we have shown that activation of PPARγ by troglitazone induces apoptosis in HepG2 cells through down-regulation of the expression of COX-2 and Bcl-2, up-regulation of bax and bak, and activation of caspase-3. Consistent with other potential chemopreventive agents in human liver cancer model, we believe that COX-2, bak, bax, bcl-2 and caspase-3 play some roles in the process of PPARγ activation-induced apoptosis. These serve as potential targets for future drugs or therapies for prevention and treatment of liver cancer.

REFERENCES
1. Evans RM. The steroid and thyroid hormone receptor superfamily. Science 1988; 240: 889-895
2. Spiegelman BM. PPAR gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998; 47: 507-514
3. Blumberg B, Evans RM. Orphan nuclear receptors: new ligands and new possibilities. Gene Dev 1998; 12: 3149-3155
4. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999; 20: 649-688
5. Murko U, Ohyama T, Imaichi H, Ishida T, Cao WM, Takahara J. Ea pha stimulation of MCP-1 expression is mediated by the Akt/PKB signal transduction pathway in vascular endothelial cells. Biochem Biophys Res Commun 2000; 276: 791-796
6. Willson TM, Brown PJ, Skernbach DD, Henke BR. The PPARIso from orphan receptors to drug discovery. J Med Chem 2000; 43: 527-550
7. Wu GD. Nuclear receptor to prevent colon cancer. N Engl J Med 2000; 342: 651-653
8. Zhu Y, Qi C, Korenberg JR. Structural organization of mouse peroxisome proliferator-activated receptor γ (mRNA) gene: alternative promoter use and different splicing yield two mPPARγ isoforms. Proc Natl Acad Sci USA 1995; 92: 7921-7925
9. Fajas L, Frucht J, Auwerx J. PPARγ mRNA: A distinct PPARγ mRNA subtype transcribed from an independent promoter. FEBS Lett 1998; 438: 55-60
10. Fajas L, Auboeuf D, Raspe E. The organization, promoter analysis, and expression of the human PPARγ gene. J Biol Chem 1997; 272: 18779-18789
11. Escher P, Wahli W. Peroxisome proliferator-activated receptors: Insight into multiple cellular functions. Nat U S 2000; 448: 121-138
12. Shao D, Rangwala SM, Bailey ST. Interdomain communication regulating ligand binding by PPAR. Nature 1998; 396: 377-380
13. Moras D, Gronemeyer H. The nuclear receptor ligand-binding domain: Structure and function. Curr Opin Cell Biol 1998; 3: 384-391
14. Lebowitz M, Fievet C, Hennuyer N. Activation of PPARδ regulates lipid metabolism in db/db mice. FEBS Lett 2000; 473: 333-336
15. Liang YC, Tsai SH, Tsai DC, Lin-Shiau SY, Lin JK. Suppression of inducible cyclooxygenase and nitric oxide synthase through activation of Peroxisome proliferator-activated receptor by flavonoids in mouse macrophages. FEBS Lett 2001; 496: 12-18
16. Kubuta T, Keshizuka K, Williamson EA. Ligand for Peroxisome proliferator-activated receptorα has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res 1998; 58: 344-355
17. Takahashi N, Okumaura T, Motomura W. Activation of PPARγ regulates cell growth and induces apoptosis in human gastric cancer cells. FEBS Lett 1999; 455: 135-139
18. Dubois RN, Abramson SB, Crofford L. Cyclooxygenase in biology and disease. FASEB J 1993; 12: 1063-1073
19. Herschman HR. Prostaglandin synthase 2. Biochem Bioph Acta 1999; 1299: 125-140
20. Eberhart CE, Coffey RJ, Radhika A. Up-regulation of cyclooxygenase-2 during sporadic colorectal carcinogenesis. Pathol 1999; 187: 295-301
21. Ristimaki A, Honkonen N, Jankala H. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 1998; 58: 2929-2934
22. Mahammed S1, Knapp DW, Bostwick DG. Expression of cyclooxygenase-2 in human invasive transitional cell carcinoma of the urinary bladder. Cancer Res 1999; 59: 5647-5650
23. Yang ZY, Rorison KA. Cyclooxygenase-2-selective antagonists do not inhibit growth of colorectal carcinoma cell lines. Cancer Letters 1999; 122: 25-30
24. Kusuhara H, Komatsu H, Sugahara K. Reactive oxygen species are involved in the apoptosis induced by NSAIDs in cultured gastric cells. Eur J Pharmacol 1999; 383: 331-337
25. Tanaka K, Pracyck JB, Takeda K, Yu ZX, Finkel T. Expression of Id1 results in apoptosis of cardiac myocytes through a redox-dependent mechanism. J Biol Chem 1998; 273: 25922-25928
26. Kim YB, Kim GE, Cho NH, Pyo HR, Shim SJ, Chang SK, Park HC, Suh CO, Park TK, Kim RS. Overexpression of cyclooxygenase-2 is associated with a poor prognosis in patients with squamous cell carcinoma of the uterine cervix treated with radiation and concurrent chemotherapy. Cancer 2002; 95: 531-539
27. Ferrandina G, Legge F, Ranellotto FO, Zannoni GF, Maggioni N, Evangelisti A, Mancuso S, Scambia G, Lauriola L. Cyclooxygenase-2 expression in endometrial carcinoma. Cancer 2002; 95: 801-8012
28. Tang X, Sun YJ, Half E, Kuo MT, Sinicrope F. Cyclooxygenase-2 overexpression inhibits death receptor 5 expression and confers resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human colon cancer cells. Cancer 2002; 82: 4903-4908
29. Staats P. Pain Management and beyond, evolving concepts and treatments involving cyclooxygenase inhibition. J Pain Symptom Manage 2002; 24: 54
30. Lin DT, Subbaramaiyah K, Shah JP, Dannenberg AJ, Boyle JO. Cyclooxygenase-2: A novel molecular target for the prevention and treatment of head and neck cancer. Head Neck 2002; 24: 792-799
31. Jiang XH, Lam SK, Lin MC, Jiang SH, Kung HF, Slosberg ED, Soh JW, Weinstein IB, Wong BC. Novel target for induction of apoptosis by cyclooxygenase-2 inhibitor SC-236 through a protein kinase C-beta[1]-dependent pathway. Oncogene 2002; 21: 6113-6122
32. He Q, Luo X, Huang Y, Sheikh MS. Apo2L/TRAIL differentially modulates the apoptotic effects of sulindac and a COX-2 selective non-steroidal anti-inflammatory agent in Bax-deficient cells. Oncogene 2002; 21: 6032-6040
Kiirpark K. Ogunlokade W, Elkak A, Bustin S, Jenkins P, Ghilchik M, Mokbel K. The mRNA expression of cyclooxygenase-2 (COX-2) and vascular endothelial growth factor (VEGF) in human breast cancer. Curr Med Res Opin 2002; 18: 237-241

Tapiero H, Ba GN, Couvreur P, Tew KD. Polyunsaturated fatty acids (PUFA) and eicosanoids in human health and pathologies. Biomed Pharmacother 2002; 56: 215-222

Badawi AF, Habib SL, Mohammed MA, Abadi AA, Michael MS. Influence of cigarette smoking on prostaglandin synthesis and cyclooxygenase-2 gene expression in human urinary bladder cancer. Cancer Invest 2002; 20: 651-656

Gallo O, Masini E, Bianchi B, Bruschini L, Paglierani M, Franchi A. Prognostic significance of cyclooxygenase-2 pathway and angiogenesis in head and neck squamous cell carcinoma. Hum Pathol 2002; 33: 708-714

Li HL, Zhang HW, Chen DD, Zhong L, Ren XD, Si-Tu R. JTE-522, a selective COX-2 inhibitor, inhibits cell proliferation and induces apoptosis in RL-95-2 cells. Acta Pharmacol Sin 2002; 23: 631-637

Li HL, Chen DD, Li XH, Zhang HW, Lu YQ, Ye CL, Ren XD. Changes of NF-kB, p53, Bcl-2 and caspase in apoptosis induced by JTE-522 in human gastric adenocarcinoma cell line AGS cells: role of reactive oxygen species. World J Gastroenterol 2002; 8: 433-435

Li HL, Chen DD, Li XH, Zhang HW, Lu JH, Ren XD, Wang CC. JTE-522-induced apoptosis in human gastric adenocarcinoma cell line AGS is mediated by caspase activation accompanying cytochrome C release, membrane translocation of Bax and loss of mitochondrial membrane potential. World J Gastroenterol 2002; 8: 217-223

Callegas NA, Castrillo A, Bosca L, Martin-Sanz P. J Pharmacol Exp Ther 1999; 288: 1235-1241

Inoue H, Tanabe T, Umeson K. Feedback control of cyclooxygenase-2 expression through PPARα. J Biol Chem 2000; 275: 28280-28282

Mead EA, McIntyre M, Zimmerman GA, Prescott SM, J Biol Chem 1999; 274: 8328-8334

Chinery R, Coffey RJ, Graves-Deal R, Kirkland SC, Sanchez SC, Morrow JD. Prostaglandin J2 and 15-deoxy-delta12,14-prostaglandin J2 induce proliferation of cyclooxygenase-depleted colorectal cancer cells. Cancer Res 1999; 59: 2739-2746

Altiok S, Xu M, Spiegelman BM. PPARγ induces cell cycle withdrawal: inhibition of E2F/DP DNA-binding activity via down-regulation of PP3A. Gene & Dev 1997; 11: 1967-1996

Tontonoz P, Singer S, Forman BM. Terminal differentiation of human liposarcoma cell induced by ligands for peroxisome proliferator-activated receptor and the retinoid X receptor. Proc Natl Acad Sci USA 1997; 94: 237-241

Demetri GD, Fletcher CD, Mueller E. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma-ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci USA 1999; 96: 3951-3956

Mueller E, Sarraf T, Tontonoz P. Terminal differentiation of human breast cancer through PPARγ, Mol Cell 1998; 1: 465-470

Suh N, Wang Y, Williams CR. A new ligand for the peroxisome proliferator-activated receptor-gamma, GW7845, inhibits rat mammary carcinogenesis. Cancer Res 1999; 59: 5671-5673

He TC, Chan TA, Vogelstein B, Kinzler KW. PPARγ is a APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 1999; 99: 335-345

Yang LW, Frucht H. Activation of the PPAR pathway induces apoptosis and COX-2 inhibition in HT-29 human colon cancer cells. Carcinogenesis 2001; 22: 1379-1383

Lefevbre AM, Chen I, Desreuxa P, Najib I, Auwerx J. Activation of peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J APCMin/+ mice. Nature 1999; 4: 1053-1057

Leducer D. Tracing the Origins of COX-2 Inhibitors’ Structures. Curr Med Chem 2002; 9: 1457-1461

Kawabe A, Shimada Y, Uchida S, Maeda M, Yamasaki S, Kato M, Hashimoto Y, Oshino G, Matsumoto M, Imamura M. Expression of cyclooxygenase-2 in primary and remnant gastric carcinoma: comparing it with p53 accumulation, Helicobacter pylori infection, and vascular endothelial growth factor expression. J Surg Oncol 2002; 80: 79-88

Kong G, Kim EK, Kim WS, Lee KT, Lee YW, Lee JK, Paik SW, Rhee JC. Role of cyclooxygenase-2 and inducible nitric oxide synthase in pancreatic cancer. J Gastroenterol Hepato 2002; 17: 914-921

Liu CM, Hong CY, Sun CT, Hsiao TY, Wang CC, Wang JS, Hsiao M, Lin SK. Inducible cyclooxygenase and interleukin 6 gene expressions in nasal polyt fibroblasts: possible implication in the pathogenesis of nasal polyps. Arch Otolaryngol Head Neck Surg 2002; 128: 945-951

Maitra A, Ashfaq R, Gunn CR, Rahman A, Yeo CJ, Sohn TA, Cameron JL, Hruban RH, Wilentz RE. Cyclooxygenase 2 expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasia: an immunohistochemical analysis with automated cellular imaging. Am J Clin Pathol 2002; 118: 194-201

Carlton PS, Gopalakrishnan R, Gupta A, Habib S, Morse MA, Stoner GD. Piroxicam is an ineffective inhibitor of N-nitrosomethylbenzylamine-induced tumorigenesis in the rat esophagus. Cancer Res 2002; 62: 4376-4382

Hoozemans JJ, Bruckner MK, Rozemuller AJ, Veerhuis R, Eekelenboom P, Arendt T. Cyclin D1 and cyclin E are co-localized with cyclooxygenase-2 (COX-2) in pyramidal neurons in Alzheimer disease temporal cortex. J Neuropathol Exp Neurol 2002; 61: 678-688

Wei M, Waniubuchi H, Morimura K, Iwai S, Yoshida K, Endo G, Fukushima S. Carcinogenicity of dimethylarsinic acid in male F344 rats and genetic alterations in induced urinary bladder tumors. Carcinogenesis 2002; 23: 1387-1397

Sunayama K, Konno H, Nakamura T, Kashiwabara H, Shoji T, Tsuneyoshi T, Nakamura S. The role of cyclooxygenase-2 (COX-2) in two different morphological stages of intestinal polyps in APC (Delta474) knockout mice. Carcinogenesis 2002; 23: 1351-1359

Wu T, Han C, Lenz JG, Michaelopoulos G, Shelhammer JH, Demetri AJ. Involvement of 85-kd cytosolic phospholipase A2 (c) and cyclooxygenase-2 in the proliferation of human cholangiocarcinoma cells. H Hepatology 2002; 36: 363-373

Wardlaw SA, Zhang N, Belinsky SA. Transcriptional regulation of basal cyclooxygenase-2 expression in murine lung tumor-derived cell lines by CCAAT/ enhancer-binding protein and activating transcription factor/ cAMP response element-binding protein. Mol Pharmacol 2002; 62: 326-333

Shah T, Ryu S, Lee HJ, Brown S, Kim JH. Pronounced radiosensitization of cultured human cancer cells by COX inhibitor under acidic microenvironment. Int J Radiat Oncol Biol Phys 2002; 53: 1314-1318

Lew JI, Guo Y, Kim RK, Vargish L, Michelassi F, Arenas RB. Reduction of Intestinal Neoplasia With a Denatopolysis Coli Gene Replacement and COX-2 Inhibition Is Additive. J Gastrointest Surg 2002; 6: 563-568

Qiu DK, Ma X, Peng YS, Chen XY. Significance of cyclooxygenase-2 expression in human primary hepatocellular carcinoma. World J Gastroenterol 2002; 8: 815-817

Tian G, Yu JP, Luo HS, Yu BP, Yue H, Li JY, Me Q. Effect of nimesulide on proliferation and apoptosis of human hepatoma SMMC-7721 cells. World J Gastroenterol 2002; 8: 483-487

Wu YL, Sun B, Zhang XJ, Wang SN, He HY, Qiao MM, Zhong J, Xu JY. Growth inhibition and apoptosis induction of Sulindac on Human gastric cancer cells. World J Gastroenterol 2001; 7: 796-800

Wang X, Lan M, Wu HP, Shi YQ, Lu J, Ding J, Wu KC, Jin JP, Fan DM. Direct effect of croton oil on intestinal epithelial cells and colonic smooth muscle cells. World J Gastroenterol 2002; 8: 103-107

Niou ZS, Li BK, Wang M. Expression of p53 and C-myc genes and its clinical relevance in the hepatocellular carcinoma and pericarcinomatous tissues. World J Gastroenterol 2002; 8: 822-826

Chen Q, Yang GW, An LG. Apoptosis of hepatoma cells SMMC-7721 induced by Ginkgo biloba seed polysaccharide. World J Gastroenterol 2002; 8: 832-836

Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis. Natl Cancer Inst 1999; 90: 1529-1536
Zimmermann KC, Sarbia M, Weber AA, Borchard F, Gabbert HE, Schror K. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res 1999; 59: 198-204.

Tjandrawinata RR, Dahiya R, Hughes FM. Induction of cyclooxygenase-2 mRNA by prostaglandin E2 in human prostatic carcinoma cells. Br J Cancer 1997; 75: 1111-1118.

Zhao AG, Zhao HL, Jin XJ, Yang JK, Tang LD. Effects of Chinese Jianpi herbs on cell apoptosis and related gene expression in human gastric cancer grafted onto nude mice. World J Gastroenterol 2002; 8: 792-796.

Liu S, Wu Q, Ye XF, Cai JH, Huang ZW, Su WJ. Induction of apoptosis by TPA and VP-16 is through translocation of TR3. World J Gastroenterol 2002; 8: 446-450.

Xu CT, Huang LT, Pan BR. Current gene therapy for stomach carcinoma. World J Gastroenterol 2001; 7: 752-759.

Wu YL, Sun B, Zhang XJ, Wang SN, He HY, Qiao MM, Zhong J, Xu JY. Growth inhibition and apoptosis induction of Sulindac on Human gastric cancer cells. World J Gastroenterol 2001; 7: 796-800.

Hou L, Li Y, Jia YH, Wang B, Xin Y, Ling MY. Molecular mechanism about lymphogenous metastasis of hepatocarcinoma cells in mice. World J Gastroenterol 2001; 7: 532-536.

Xu AG, Li SG, Liu JH, Gan AH. Function of apoptosis and expression of the proteins Bcl-2, p53 and C-myc in the development of gastric cancer. World J Gastroenterol. 2001; 7: 403-406.